Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
Eileen Shiuan(Vanderbilt University), Kathryn E. Beckermann(Vanderbilt University Medical Center), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Eric Jonasch(The University of Texas MD Anderson Cancer Center), Gregory Riedlinger(Rutgers, The State University of New Jersey), Scott M. Haake(Vanderbilt University Medical Center), Aaron R. Lim(Vanderbilt University), Joolz Ward(Thermo Fisher Scientific (United States)), Benjamin G. Vincent(University of North Carolina at Chapel Hill), Brian I. Rini(Vanderbilt University Medical Center), Stephanie O. Dudzinski(The University of Texas MD Anderson Cancer Center), Renee McAlister(Vanderbilt University Medical Center), Kristen Ruma(Navidea Biopharmaceuticals (United States)), Anupama Reddy(Rutgers, The State University of New Jersey), Xian-De Liu(The University of Texas MD Anderson Cancer Center), Kimberly B. Dahlman(Vanderbilt University), Kirsten Young, Ayaka Sugiura(Vanderbilt University Medical Center), Jehovana O. Bender(Navidea Biopharmaceuticals (United States)), Jeffrey C. Rathmell(University of Chicago), Shridar Ganesan(Rutgers, The State University of New Jersey), Christof C. Smith(Dana-Farber Cancer Institute), Tina Mayer(Hochschule Hannover), Christine Vaupel(Navidea Biopharmaceuticals (United States)), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Nathan Roscoe(Navidea Biopharmaceuticals (United States)), Beiru Chen(Lineage Cell Therapeutics (United States)), Nancy B. Davis(Vanderbilt University Medical Center), Rachel A. Hongo, Ju Young Kim(Navidea Biopharmaceuticals (United States)), Jamye F. O’Neal(Vanderbilt University Medical Center)
Cited by 16
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
|The Journal of Immunology|2011|2k
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
|Nature|2011|1.4k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k